J&J takes Carlyle's $4B offer for its Ortho Diagnostics unit

Johnson & Johnson ($JNJ) agreed to unload its Ortho Clinical Diagnostics unit to the private equity firm Carlyle Group in a $4.15 billion deal. J&J said last year it wanted to shed the underperforming business, and analysts now predict that the company will put other business units on the block. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.